Side-by-side · Research reference
ARA 290vsMGF
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED17/59 cited
BAnimal-StrongHUMAN-REVIEWED14/55 cited
MGF
IGF-1Ec Splice Variant · Muscle-Specific
SQ · Research context only
01Mechanism of Action
Parameter
ARA 290
MGF
Primary target
Innate repair receptor (EPO receptor / CD131 heterodimer)
Satellite cells (Pax7+) in skeletal muscleMoore 2018
Pathway
EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades
Mechanical stress → IGF-1Ec mRNA upregulation → Local E-domain peptide release → Satellite cell activation
Downstream effect
Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014Culver 2017
Satellite cell proliferation, myoblast differentiation, muscle fiber repair
Origin
11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties
Alternative splicing of IGF-1 gene (exons 4-6) produces IGF-1Ec precursor; E-domain cleaved post-translationallyArmakolas 2016Vassilakos 2017
Antibody development
Not reported in clinical trials
—
02Dosage Protocols
Parameter
ARA 290
MGF
Standard dose (Phase 2)
4 mg / dayBrines 2015Culver 2017
Sarcoidosis SFN and diabetic neuropathy trials.
—
Frequency
Once daily
Self-administered subcutaneously.
—
Evidence basis
Phase 2 RCTsCulver 2017Brines 2015
64-subject sarcoidosis trial, type 2 diabetes trial.
Animal models + in vitro only
Timing
Any time of day
No circadian dependence reported.
—
Synthetic peptide
—
24-amino-acid E-domain sequence
Corresponds to human IGF-1Ec exons 4-6 region.
Rodent cardiac model
—
200 μg/kg via peptide-eluting microstructures
Post-MI injection; improved ejection fraction by 8 weeks.
Acute delivery (mouse MI)
—
Single bolus within 12 hrs post-infarctionShioura 2014
Delayed decompensation; no human protocol established.
Human evidence
—
None — no published clinical trials
All dosing extrapolated from animal models.
Detection in doping
—
Full-length MGF detected via LC-MS in illicit productsThevis 2014
WADA-prohibited since 2005; no therapeutic indication.
03Metabolic / Fat Loss Evidence
Parameter
ARA 290
MGF
Primary effect
Improved metabolic control (HbA1c, fasting glucose)Brines 2015
Secondary to neuropathy treatment; direct lipolytic effects not established.
—
HbA1c
Significant reduction vs placebo
Observed in type 2 diabetes + neuropathy trial.
—
Fasting glucose
Improved in ARA 290 group
—
Body composition
Not directly quantified
Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.
—
04Side Effects & Safety
Parameter
ARA 290
MGF
Injection site reaction
Mild, transient
—
Hematopoiesis
None — non-erythropoietic
Distinguishes ARA 290 from native EPO.
—
Cardiovascular
No thrombotic events or hypertension reported
—
Immunogenicity
No antibody formation reported
—
Human safety data
—
None — no clinical trials published
Theoretical IGF-1 axis risk
—
Chronic IGF-1Ec overexpression linked to cancer progression (prostate, colorectal, breast)
Tumor promotion
—
IGF-1Ec overexpressed in osteosarcoma, colorectal polyps with dysplasia, endometrial cancer
Antibody development
—
Unknown — no longitudinal human exposure data
Local injection reaction
—
Presumed similar to other peptides (erythema, induration) — no direct evidence
Dysregulated expression with age
—
Older adults (70+ yrs) show blunted IGF-1Ec response post-exercise vs youngMoore 2018
Absolute Contraindications
ARA 290
- ·Hypersensitivity to ARA 290
MGF
- ·Active malignancy or history of IGF-1-sensitive cancers (prostate, colorectal, breast, osteosarcoma)
- ·No established therapeutic use — investigational only
Relative Contraindications
ARA 290
- ·Active malignancy (theoretical EPO-axis concern; not observed in trials)
MGF
- ·Family history of IGF-1-axis malignancies
- ·Use outside research setting
05Administration Protocol
Parameter
ARA 290
MGF
1. Preparation
Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.
MGF (E-domain peptide) has no approved clinical protocol. All published data derive from animal models or in vitro experiments.
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.
Commercially available MGF corresponds to the 24-amino-acid human E-domain (hEc). Rodent E-domain (Eb) is structurally distinct and not interchangeable.
3. Timing
Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015
Rodent studies used peptide-eluting polymeric microstructures (cardiac) or direct intramuscular injection. Routes and doses non-translatable to humans.Peña 2015Shioura 2014
4. Dosing
4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017
MGF peptides prohibited in sport since 2005. Detection via LC-MS established for full-length MGF products.Thevis 2014
5. Storage
Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.
Any human use falls outside approved medical practice and regulatory frameworks. No safety or efficacy data exist.
06Stack Synergy
ARA 290
+ BPC-157
ModerateARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.
- ARA 290
- 4 mg SQ · daily
- BPC-157
- 250–500 mcg SQ · daily
- Frequency
- Once daily, same or separate injections
- Primary benefit
- Nerve regeneration, pain reduction, tissue healing
MGF
+ BPC-157
Multi-pathwayMGF activates satellite cells for muscle fiber repair; BPC-157 promotes angiogenesis, collagen synthesis, and tendon healing via distinct pathways (VEGF, FAK, integrin signaling). Theoretical synergy in post-injury contexts combines myogenic (MGF) and stromal (BPC-157) repair mechanisms. Both lack human validation.
- MGF
- No established dose
- BPC-157
- 250–500 mcg SQ near injury site
- Context
- Animal models only
- Primary benefit
- Theoretical multi-tissue repair (muscle + tendon/ligament)
+ TB-500
ModerateTB-500 (thymosin beta-4 fragment) enhances actin polymerization, cell migration, and angiogenesis—complementary to MGF satellite cell activation. Both upregulated post-injury; combined use presumed additive for muscle regeneration in preclinical models.
- MGF
- No established dose
- TB-500
- 2–5 mg SQ weekly
- Context
- Animal models only
- Primary benefit
- Satellite cell activation + enhanced migration/angiogenesis